AJP - Renal Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol 295: F1624-F1634, 2008. First published September 3, 2008; doi:10.1152/ajprenal.00032.2008
0363-6127/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/6/F1624    most recent
00032.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Artunc, F.
Right arrow Articles by Lang, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Artunc, F.
Right arrow Articles by Lang, F.

Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome

Ferruh Artunc,1,2 Omaima Nasir,1 Kerstin Amann,3 Krishna M. Boini,1 Hans-Ulrich Häring,2 Teut Risler,2 and Florian Lang1

Departments of 1Physiology and of 2Internal Medicine IV, University of Tübingen, Tübingen; and 3Department of Pathology, University of Erlangen, Erlangen, Germany

Submitted 22 January 2008 ; accepted in final form 2 September 2008

Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis. The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess. The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome. To this end, doxorubicin (15 µg/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1–/–) and their wild-type littermates (sgk1+/+). Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1+/+ and 15/44 of sgk1–/– mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes. Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1+/+ mice. Urinary sodium excretion reached signficantly lower values in sgk1+/+ mice (15 ± 5 µmol/mg crea) than in sgk1–/– mice (35 ± 5 µmol/mg crea) and was associated with a significantly higher body weight gain in sgk1+/+ compared with sgk1–/– mice (+6.6 ± 0.7 vs. +4.1 ± 0.8 g). During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1–/– mice than in sgk1+/+ mice leading to uremia and a reduced median survival in sgk1–/– mice (29 vs. 40 days in sgk1+/+ mice). In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.

sodium; ascites; mice; proteinuria



Address for reprint requests and other correspondence: F. Artunc, Dept. of Internal Medicine IV, Univ. Hospital of Tübingen, Otfried-Mueller-Str. 10, 72076 Tübingen, Germany (e-mail: ferruh.artunc{at}med.uni-tuebingen.de) and F. Lang, Dept. of Physiology, Univ. of Tübingen, Gmelinstr. 5, 72076 Tübingen, Germany (e-mail: florian.lang{at}uni-tuebingen.de)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.